Monitoring Salivary Misonidazole in Man: a Possible Alternative to Plasma Monitoring

Overview

Journal Br J Cancer

Specialty Oncology

Date 1978 Dec 1

PMID 743488

Citations 10

Authors

P Workman

C R Wiltshire

P N Plowman

N M Bleehen

Affiliations

Soon will be listed here.

Abstract

Concentrations of misonidazole and its O-demethylated metabolite Ro 05-9963 in the plasma and saliva of 10 patients with malignant disease have been determined. A good linear correlation was established between plasma and saliva misonidazole concentration, and salivary sampling was found to be suitable for the estimation of a number of pharmacokinetic parameters. Data are also presented for serial tumour cencentrations of misonidazole and Ro 05-9963 in 3 of the 10 patients. Monitoring of salivary misonidazole concentration appears to be a useful alternative to plasma monitoring, particularly for those patients in whom plasma sampling is unsuitable or impossible.

Citing Articles

Saliva as a sampling source for the detection of leukemic fusion transcripts.

Chen D, Song N, Ni R, Zhao J, Hu J, Lu Q J Transl Med. 2014; 12:321.

PMID: 25407125 PMC: 4243783. DOI: 10.1186/s12967-014-0321-z.

Nicotinamide pharmacokinetics in humans: effect of gastric acid inhibition, comparison of rectal vs oral administration and the use of saliva for drug monitoring.

Stratford M, Dennis M, Hoskin P, Phillips H, Hodgkiss R, Rojas A Br J Cancer. 1996; 74(1):16-21.

PMID: 8679452 PMC: 2074616. DOI: 10.1038/bjc.1996.309.

Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice.

Workman P Cancer Chemother Pharmacol. 1980; 5(1):27-37.

PMID: 7460192 DOI: 10.1007/BF00578559.

A rapid and specific semi-micro method involving high-pressure liquid chromatography for the assay of metronidazole in plasma, saliva, serum, urine and whole blood.

Kaye C, Sankey M, Thomas L Br J Clin Pharmacol. 1980; 9(5):528-9.

PMID: 7397071 PMC: 1429966. DOI: 10.1111/j.1365-2125.1980.tb05856.x.

Phenytoin shortens the half-life of the hypoxic cell radiosensitizer misonidazole in man: implications for possible reduced toxicity.

Workman P, Bleehen N, Wiltshire C Br J Cancer. 1980; 41(2):302-4.

PMID: 7370170 PMC: 2010192. DOI: 10.1038/bjc.1980.43.

References

KOSTLIN A, Rauch S . [Chemistry of residual saliva of a single salivary gland]. Helv Med Acta. 1957; 24(5):600-21. View

HORNING M, Brown L, Nowlin J, Lertratanangkoon K, KELLAWAY P, Zion T . Use of saliva in therapeutic drug monitoring. Clin Chem. 1977; 23(2 PT. 1):157-64. View

SPEIRS C . Oral absorption and secretion of drugs. Br J Clin Pharmacol. 1977; 4(2):97-100. PMC: 1429012. DOI: 10.1111/j.1365-2125.1977.tb00678.x. View

. Salivary concentrations of antiepileptic drugs. Lancet. 1976; 2(7986):639-40. View

Wiltshire C, Workman P, Watson J, Bleehen N . Clinical studies with misonidazole. Br J Cancer Suppl. 1978; 3:286-9. PMC: 2149437. View

Workman P, Little C, Marten T, DALE A, Ruane R, Flockhart I . Estimation of the hypoxic cell-sensitiser misonidazole and its O-demethylated metabolite in biological materials by reversed-phase high-performance liquid chromatography. J Chromatogr. 1978; 145(3):507-12. DOI: 10.1016/s0378-4347(00)81386-9. View

Dische S, Saunders M, Lee M, Adams G, Flockhart I . Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses. Br J Cancer. 1977; 35(5):567-79. PMC: 2025511. DOI: 10.1038/bjc.1977.90. View

Urtasun R, Band P, Chapman J, Rabin H, Wilson A, Fryer C . Clinical phase I study of the hypoxic cell radiosensitizer RO-07-0582, a 2-nitroimidazole derivative. Radiology. 1977; 122(3):801-4. DOI: 10.1148/122.3.801. View

Stephen K, SPEIRS C . Methods for collecting individual components of mixed saliva: the relevance to clinical pharmacology. Br J Clin Pharmacol. 1976; 3(2):315-9. PMC: 1428867. DOI: 10.1111/j.1365-2125.1976.tb00609.x. View

10.

Perrier D, Gibaldi M . Clearance and biologic half-life as indices of intrinsic hepatic metabolism. J Pharmacol Exp Ther. 1974; 191(1):17-24. View

11.

Wilkinson G, SHAND D . Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975; 18(4):377-90. DOI: 10.1002/cpt1975184377. View

12.

Graham G, Rowland M . Application of salivary salicylate data to biopharmaceutical studies of salicylates. J Pharm Sci. 1972; 61(8):1219-22. DOI: 10.1002/jps.2600610810. View

13.

SPEIRS C, STENHOUSE D, Stephen K, WALLACE E . Comparison of human serum, parotid and mixed saliva levels of phenoxymethylpenicillin, ampicillin, cloxacillin and cephalexin. Br J Pharmacol. 1971; 43(1):242-7. PMC: 1665947. DOI: 10.1111/j.1476-5381.1971.tb07173.x. View

14.

Gray A, Dische S, Adams G, Flockhart I, Foster J . Clinical testing of the radiosensitiser Ro-07-0582. I. Dose tolerance, serum and tumour concentrations. Clin Radiol. 1976; 27(2):151-7. DOI: 10.1016/s0009-9260(76)80137-7. View

15.

Adams G, Flockhart I, Smithen C, Stratford I, Wardman P, Watts M . Electron-affinic sensitization. VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers. Radiat Res. 1976; 67(1):9-20. View

16.

Asquith J, Watts M, Patel K, Smithen C, Adams G . Electron affinic sensitization. V. Radiosensitization of hypoxic bacteria and mammalian cells in vitro by some nitroimidazoles and nitropyrazoles. Radiat Res. 1974; 60(1):108-18. View